Eli Lilly and Novo Nordisk raise profit outlook as weight-loss drug demand soars

Eli Lilly and Novo Nordisk have both raised their profit forecasts due to the skyrocketing demand for their weight-loss drugs, signaling a significant shift in the pharmaceutical market. While this surge is a boon for their bottom lines, investors are wary of Novo Nordisk’s heavy reliance on obesity treatments, which could pose risks if trends change. This divergence in market perception highlights the delicate balance companies face between capitalizing on current trends and maintaining a diversified product portfolio. The developments underscore the growing importance of weight-loss medications in the healthcare industry.